About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Marc Güell Cargoll, ICREA Research Professor at Pompeu Fabra University.
Department: Department of Medicine and Life Sciences. Research groups: Translational SYNBIO
Abstract: Our research is focussed in developing new principles and technologies to engineer biological systems. AI is revolutionizing biodesign, and its coupling with multiplex DNA writing enables a new concept of synthetic evolution which promises to accelerate synthetic biology. We are levereging bioprospecting, AI and evolution to create new biological functions. Then, I will focus on 1) how we developed a gene writer for human cells and its deployment ex vivo (T cells) and in vivo (liver targeting, in vivo T cells). 2) how we use Cutibacterium acnes as a chassis to engineer human skin properties.
Online assistance: https://gencat.zoom.us/j/85369764056
In-person attendance: https://valldhebron.typeform.com/SeminarSeries2
